STK25 and hepatocellular carcinoma: Together, the results of our investigations, which combine in vivo analyses in mouse models with expression profiling in human liver biopsies and in vitro assessments in cultured human hepatoma cells, demonstrate that antagonizing STK25 signaling mitigates the development and progression of MASH-driven HCC.